FDA Approves Subcutaneous Version of Biogen and Eisai's Alzheimer's Treatment Leqembi
The U.S. Food and Drug Administration (FDA) has approved the subcutaneous version of Biogen and Eisai’s Alzheimer's treatment, Leqembi Iqlik (lecanemab), for initiation and maintenance dosing as well as at-home use.
Tickers: $BIIB